{
  "nctId": "NCT05743387",
  "briefTitle": "Community-based, eHealth Supported Type 2 Diabetes Care by Lay Village Health Workers in Rural Lesotho",
  "officialTitle": "Community-based, eHealth Supported Type 2 Diabetes Care by Lay Village Health Workers in Rural Lesotho Protocol for a Cluster-randomized Trial Within the ComBaCaL Cohort Study (ComBaCaL T2D TwiC)",
  "protocolDocument": {
    "nctId": "NCT05743387",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan: Protocol",
    "date": "2023-02-03",
    "uploadDate": "2023-10-10T08:46",
    "size": 1265159,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT05743387/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "SINGLE",
  "enrollmentInfo": {
    "enrollmentCount": 253,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2023-05-13",
    "completionDate": "2026-05-31",
    "primaryCompletionDate": "2025-03-23",
    "firstSubmitDate": "2023-02-14",
    "firstPostDate": "2023-02-24"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Participant of the ComBaCaL cohort study (signed informed consent available)\n* Living with T2D, defined as reporting intake of antidiabetic medication or being newly diagnosed during screening via standard diagnostic algorithm\n\nExclusion Criteria:\n\n* Known type 1 diabetes mellitus\n* Reported pregnancy",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Mean HbA1c (in percent)",
        "description": "Mean HbA1c (in percent)",
        "timeFrame": "12 months after enrolment"
      }
    ],
    "secondary": [
      {
        "measure": "Change in 10-year CVD risk estimated",
        "description": "Change in 10-year CVD risk estimated using the World Health Organization (WHO) CVD risk prediction tool",
        "timeFrame": "6 and 12 months after enrolment"
      },
      {
        "measure": "Mean HbA1c (in percent)",
        "description": "Mean HbA1c (in percent)",
        "timeFrame": "6 months after enrolment"
      },
      {
        "measure": "Change in mean fasting blood glucose (FBG) (mmol/l)",
        "description": "Change in mean fasting blood glucose (FBG) (mmol/l)",
        "timeFrame": "6 and 12 months after enrolment"
      },
      {
        "measure": "Change in proportion of participants with an HbA1c below 8%",
        "description": "Change in proportion of participants with an HbA1c below 8%",
        "timeFrame": "6 and 12 months after enrolment"
      },
      {
        "measure": "Change in proportion of participants with an FBG below 7 mmol/l",
        "description": "Change in proportion of participants with an FBG below 7 mmol/l",
        "timeFrame": "6 and 12 months after enrolment"
      },
      {
        "measure": "Change in number of CVD risk factors",
        "description": "Change in number of CVD risk factors (such as smoking status, BMI, abdominal circumference, blood lipid status, blood pressure, dietary habits and physical activity)",
        "timeFrame": "6 and 12 months after enrolment"
      },
      {
        "measure": "Linkage to care: Change in proportion of participants not taking treatment at enrolment who have initiated pharmacological antidiabetic treatment",
        "description": "Change in proportion of participants not taking treatment at enrolment who have initiated pharmacological antidiabetic treatment",
        "timeFrame": "6 and 12 months after enrolment"
      },
      {
        "measure": "Engagement in care: Change in proportion of participants who are engaged in care",
        "description": "Change in proportion of participants who are engaged in care, defined as reporting intake of antidiabetic medication as per prescription of a healthcare provider or reaching treatment targets without intake of medication",
        "timeFrame": "6 and 12 months after enrolment"
      },
      {
        "measure": "Change in self-reported adherence to antidiabetic medication",
        "description": "Change in self-reported adherence to antidiabetic medication",
        "timeFrame": "6 and 12 months after enrolment"
      },
      {
        "measure": "Occurrence of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)",
        "description": "Occurrence of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)",
        "timeFrame": "within 6 and 12 months after enrolment"
      }
    ],
    "other": [
      {
        "measure": "Number of consultations (at a health facility and with the CC-VHW)",
        "description": "Number of consultations at a health facility and with the CC-VHW",
        "timeFrame": "within 6 and 12 months after enrolment"
      },
      {
        "measure": "Trajectory of participants between facility-based and community-based care in the intervention villages",
        "description": "Trajectory of participants between facility-based and community-based care in the intervention villages (i.e. number of participants accepting community-based care at baseline, number of people switching to facility-based care and back to community-based care",
        "timeFrame": "during the study period (up to 12 months)"
      },
      {
        "measure": "Proportion of participants with T2D who stop drug treatment or interrupt drug treatment for more than three weeks or require a switch of drug treatment due to (perceived) adverse events (AEs)",
        "description": "Proportion of participants with T2D who stop drug treatment or interrupt drug treatment for more than three weeks or require a switch of drug treatment due to (perceived) adverse events (AEs)",
        "timeFrame": "within 6 and 12 months after enrolment"
      },
      {
        "measure": "Change in proportion of participants who are reaching treatment targets (FBG <7 mmol/l) and are reporting no intake of antidiabetic medication in the two weeks prior to assessment",
        "description": "Change in proportion of participants who are reaching treatment targets (FBG \\<7 mmol/l) and are reporting no intake of antidiabetic medication in the two weeks prior to assessment",
        "timeFrame": "6 and 12 months after enrolment"
      },
      {
        "measure": "Change in proportion of participants accessing lipid-lowering medication",
        "description": "Change in proportion of participants accessing lipid-lowering medication",
        "timeFrame": "6 and 12 months after enrolment"
      },
      {
        "measure": "Change in health system costs for the management of participants condition",
        "description": "Change in health system costs for the management of participants condition",
        "timeFrame": "within 6 and 12 months after diagnosis"
      },
      {
        "measure": "Change in individual costs for participants for the management of their condition",
        "description": "Change in individual costs for participants for the management of their condition",
        "timeFrame": "within 6 and 12 months after diagnosis"
      },
      {
        "measure": "Change in10-year CVD risk estimated using the Globorisk score",
        "description": "Change in10-year CVD risk estimated using the Globorisk score, a cardiovascular disease risk score that predicts risk of heart attack or stroke in healthy individuals for all countries in the world. It uses information on a person's country of residence, age, sex, smoking, diabetes, blood pressure and cholesterol to predict the chance that they would have a heart attack or stroke in the next 10 years.",
        "timeFrame": "6 and 12 months after enrolment"
      },
      {
        "measure": "Change in10-year CVD risk estimated using the Framingham Risk Score",
        "description": "Change in10-year CVD risk estimated using the Framingham Risk Score, a sex-specific algorithm used to estimate the 10-year cardiovascular risk of an individual. The Framingham Risk Score was first developed based on data obtained from the Framingham Heart Study.",
        "timeFrame": "6 and 12 months after enrolment"
      },
      {
        "measure": "Quality of life (QOL) using the EQ-5D-5L instrument",
        "description": "The EQ-5D-5L is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The QOL scores are summed so that a higher score indicates higher quality of life.",
        "timeFrame": "12 months after enrolment"
      },
      {
        "measure": "Health beliefs using the Beliefs about Medicines Questionnaire (BMQ) adapted for people living with T2D",
        "description": "The BMQl comprises two 4-item factors assessing beliefs that medicines are harmful, addictive, poisons which should not be taken continuously and that medicines are overused by doctors.The items are scored on a 5 point Likert scale with scores ranging from 4 to 20.",
        "timeFrame": "12 months after enrolment"
      },
      {
        "measure": "Diabetes distress using the five item version of the \"Problem Areas in Diabetes\" (PAID-5) scale Problem Areas in Diabetes Scale-Five-item Short Form",
        "description": "Problem Areas in Diabetes Scale-Five-item Short Form. Total scores on the PAID-5 can range from 0 to 20, with higher scores suggesting greater diabetes-related emotional distress.",
        "timeFrame": "12 months after enrolment"
      },
      {
        "measure": "Change in dosage of antidiabetic medications prescribed by CC-VHWs or healthcare professionals",
        "description": "Change in dosage of antidiabetic medications prescribed by CC-VHWs or healthcare professionals",
        "timeFrame": "6 and 12 months after enrolment"
      },
      {
        "measure": "Change in dosage of lipid-lowering medications prescribed by CC-VHWs or healthcare professionals",
        "description": "Change in dosage of lipid-lowering medications prescribed by CC-VHWs or healthcare professionals",
        "timeFrame": "6 and 12 months after enrolment"
      }
    ]
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 10,
      "otherCount": 14,
      "totalCount": 25
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:08.473Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}